Drug Discovery Today
NOVEMBER 16, 2022
The team behind the success of one the country’s largest science and innovation park has announced its plans to grow and double the number of people employed on site as it celebrates a decade of delivering jobs and investment in the South East.
Chemical Biology and Drug Design
NOVEMBER 15, 2022
Sinomenine protected WI-38 cells against lipopolysaccharide-caused viability reduction, inflammation and apoptosis via downregulating glutathione S-transferase M1 expression. Abstract Pediatric pneumonia is an infectious lung disease with high morbidity and mortality. Sinomenine, an alkaloid extracted from Caulis Sinomenii , exerts anti-inflammatory and anti-apoptotic activities.
Antidote
NOVEMBER 18, 2022
Lung Cancer Awareness Month occurs every November with the purpose of increasing general knowledge of lung cancer and the treatment options available to patients who have been diagnosed. While lung cancer is still a prevalent disease, there have been many advancements in the lung cancer treatment space over the years, and medical research studies are consistently underway to find better solutions for patients.
Drug Channels
NOVEMBER 15, 2022
Last week, GoodRx announced that it would become the exclusive prescription discount card provider for the commercial beneficiaries of Cigna’s Express Scripts. Links below. The rise of discount card pricing within pharmacy benefit plans is a positive development. Patients get access to market prices that can be lower than their PBM’s contracted rate.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Discovery Today
NOVEMBER 15, 2022
A discovery that may improve treatment options for patients with neurodegenerative diseases has been made by scientists at King’s College London and the University of Bath.
Drug Patent Watch
NOVEMBER 14, 2022
This chart shows the pharmaceutical companies with the most suppository dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suppository dosed drugs…. The post Which pharmaceutical companies have the most suppository dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Conversations in Drug Development Trends
NOVEMBER 14, 2022
Psychiatry has long embraced treatment options other than pharmaceuticals. So, it should come as no surprise that as the field explores the use of psychedelics as treatment options for mental illnesses, they are studying the use of psychological therapy alongside them. This is called “psychedelic-assisted psychotherapy” (PAP). But in a clinical trial setting, what role does a therapist play and how do they affect the clinical trial data?
Drug Discovery Today
NOVEMBER 16, 2022
Collaboration with innovative Finnish software company to explore how to reduce the time and cost of drug discovery and development using quantum computers
Drug Patent Watch
NOVEMBER 12, 2022
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 18, 2022
Today’s guest post comes from Bansi Nagji, President of Healthcare at GoodRx. Bansi explains how GoodRx Provider Mode delivers a prescription savings flow that offers health care professionals (HCPs) efficient access to the information they need at critical moments of care. Click here to learn how GoodRx Provider Mode can help manufacturers reach and engage HCPs.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Metabolite Tales Blog
NOVEMBER 17, 2022
AhR activators – friend or foe? A very usual metabolite, a very unusual pharmacological target, and an unexpected serious adverse effect that combined to halt the development of laquinimod and roquinimex By Andrew Parkinson, XPD Consulting Laquinimod (Nervantra), a drug previously under development by Teva Pharmaceuticals for the treatment of multiple sclerosis, is converted by CYP-dependent N -de-ethylation to N- desethyl-laquinimod (DELAQ).
Drug Discovery Today
NOVEMBER 17, 2022
98 per cent of exhibitors sign up for Lab Innovations 2023 after a record breaking event this year
Drug Patent Watch
NOVEMBER 18, 2022
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.
The Premier Consulting Blog
NOVEMBER 16, 2022
One of the most common formulation issues that sponsors of new drug or biologic products face is the qualification of novel excipients. Although novel excipients can be a part of any new drug application (NDA) or biologics license application (BLA) development program, they seem to be more common with the 505(b)(2) pathway, since many companies use cutting-edge delivery technologies to solve issues associated with previously approved drugs.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Advarra
NOVEMBER 17, 2022
In 2016, the Food and Drug Administration (FDA) approved Spinraza (nusinersen). It was the first drug to treat children with spinal muscular atrophy (SMA), a disease affecting children’s muscular strength and movement. While the FDA’s approval of nusinersen may not seem extraordinary, it was. Nusinersen’s approval marked the first time nonclinical data supported conducting initial clinical trials involving children.
The Anticancer Fund
NOVEMBER 16, 2022
17 November 2022 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Drug Patent Watch
NOVEMBER 17, 2022
This chart shows the pharmaceutical companies with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Japan? appeared first on DrugPatentWatch - Make Better Decisions.
The Premier Consulting Blog
NOVEMBER 15, 2022
Research and development (R&D) investment decisions may be the largest risk taken by drug developers. When a single asset has broad applicability, sponsors must perform a thorough evaluation of its scientific, regulatory, clinical, patient, and commercial elements to determine the best path forward, especially if they are positioning themselves for raising capital.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Olympian Clinical Research
NOVEMBER 16, 2022
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that is not well-known. In fact, patients with HS often complain of pimples, sores or lumps on their armpits or groin area, having no idea these are actually symptoms of a more serious condition. Though it’s not well known, HS is more common than you might think, and awareness and education can help people with HS get the diagnosis and help they need.
National Drug & Alcohol Research Centre Blog
NOVEMBER 13, 2022
In September this year, NDARC awarded travel scholarships to early career researchers (ECRs) and higher degree research students (HDRs) in the alcohol and other drugs (AOD) sector. The scholarship recipients attended key events including the ASCEND Symposium, the 2022 NDARC Annual Research Symposium and the NDARC Early Career Networking Event. Gabrielle Caluzzi, a postdoctoral researcher at the Centre for Alcohol Policy Research, La Trobe University, and Carmen Lim, a PhD candidate at The Nation
Drug Patent Watch
NOVEMBER 17, 2022
Annual Drug Patent Expirations for IGALMI Igalmi is a drug marketed by Bioxcel and is included in one NDA. There is one patent protecting this drug. This drug has twenty…. The post New patent for Bioxcel drug IGALMI appeared first on DrugPatentWatch - Make Better Decisions.
Antidote
NOVEMBER 14, 2022
Increasing app downloads can feel like an uphill battle for companies in the competitive healthtech space. Because this is a crowded industry, user acquisition can be a considerable challenge — but Antidote is well-positioned to assist.
LifeSciVC
NOVEMBER 16, 2022
By Ivana Magovčević-Liebisch PhD, JD, CEO of VIGIL NEUROSCIENCE, as part of the From The Trenches feature of LifeSciVC Compared to most industries, biotech life cycles are lengthy. From R&D and clinical development to regulatory approval, it takes an average of 12 to 14 years for an idea to become a reality. Fueling the development of a novel therapeutic often requires multiple rounds of financing, and the time between rounds as well as the time from founding to initial public offering (IPO)
National Drug & Alcohol Research Centre Blog
NOVEMBER 13, 2022
In September this year, NDARC awarded travel scholarships to early career researchers (ECRs) and higher degree research students (HDRs) in the alcohol and other drugs (AOD) sector. The scholarship recipients attended key events including the ASCEND Symposium, the 2022 NDARC Annual Research Symposium and the NDARC Early Career Networking Event. Gabrielle Caluzzi, a postdoctoral researcher at the Centre for Alcohol Policy Research, La Trobe University, and Carmen Lim, a PhD candidate at The Nation
Drug Patent Watch
NOVEMBER 17, 2022
Annual Drug Patent Expirations for VEREGEN Veregen is a drug marketed by Ani Pharms and is included in one NDA. It is available from two suppliers. There are three patents…. The post New patent expiration for Ani Pharms drug VEREGEN appeared first on DrugPatentWatch - Make Better Decisions.
Drug & Device Law
NOVEMBER 17, 2022
The recent defense win in Dains v. Bayer HealthCare LLC , 2022 WL 16572021 (N.D.N.Y. Nov. 1, 2022), demonstrates why many plaintiff-side counsel are well-advised to steer away from cases involving PMA medical devices. Between federal preemption and TwIqbal , not one of the plaintiff’s “seventeen separately enumerated causes of action” escaped the defendant’s motion to dismiss.
Drug Patent Watch
NOVEMBER 16, 2022
Annual Drug Patent Expirations for XOFIGO Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent expiration for Bayer Hlthcare drug XOFIGO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 16, 2022
Annual Drug Patent Expirations for OZEMPIC Ozempic is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-five patents protecting…. The post New patent for NOVO drug OZEMPIC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 15, 2022
This chart shows the pharmaceutical companies with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Austria? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 15, 2022
Annual Drug Patent Expirations for OCALIVA Ocaliva is a drug marketed by Intercept Pharms Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent expiration for Intercept Pharms drug OCALIVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 15, 2022
Annual Drug Patent Expirations for TURALIO Turalio is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. It is available from one supplier. There are twelve…. The post New patent for Daiichi Sankyo drug TURALIO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 15, 2022
Annual Drug Patent Expirations for RADICAVA+ORS Radicava Ors is a drug marketed by Mitsubishi Tanabe and is included in one NDA. It is available from one supplier. There are two…. The post New patent for Mitsubishi Tanabe drug RADICAVA ORS appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 14, 2022
[
Expert insights. Personalized for you.
113 
Let's personalize your content